Medicago announces research collaboration with Bayer CropScience
Medicago, Inc. announced that it has entered into a product development agreement with Bayer CropScience L.P. in the field of Plant-Made Pharmaceuticals. The goal of the collaboration is to assess the feasibility of using Medicago's proprietary Proficia(TM) Protein Technology for the production of an undisclosed human therapeutic protein. It is envisioned that this will lead to further cooperation between the two companies in the area of PMPs. Terms of the agreement were not disclosed.
The Proficia(TM) Protein Technology system capitalizes on the inherent advantages of alfalfa plants to efficiently produce proteins, offering biopharmaceutical companies the flexibility and high volume potential of plant-based technology to produce therapeutic human proteins within safe, controlled environments of high-tech greenhouses. Proficia(TM) provides several advantages compared to cell culture and other biological expression systems, including: fast development time-lines and scale-up, contained and controlled manufacturing, consistent product quality, reduced contamination risk, lower production costs, flexibility of timing and reduced capital investments. The efficiency and flexibility of this technology also opens the way for the production of more specialized biotherapeutics which cannot at this time be made in a commercially feasible manner, as well as more cost-efficient production of biopharmaceuticals.
Other news from the department business & finance
